IP Library Granted Patent US 7,320,977
Granted Patent B2
US 7,320,977 · App. 10/511,225 · Granted Jan 22, 2008

Substituted 2-phenyl-3(2h)-pyridazinones

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,320,977
App. No.
10/511,225
Granted
Jan 22, 2008
Kind
B2
Abstract

The invention relates to substituted 2-Phenyl-3(2H)-Pyridazinones, to a method for the production thereof, and to their use as medicaments for the prophylaxis and/or treatment of diseases in humans and/or animals.

Claims (52)

1. A compound of the formula (I)

in which

R 1 is 5- to 7-membered, saturated or partially unsaturated heterocyclyl which is linked via a ring nitrogen atom and optionally has a further heteroatom or hetero chain member from the series N, O, S, SO or SO 2 , and which may be substituted once or twice, identically or differently, by substitutents selected from the group of halogen, (C 1 -C 6 )-alkyl, (C 2 -C 6 )-alkenyl, (C 3 -C 8 )-cycloalkyl, hydroxy, oxo, carboxyl, (C 1 -C 6 )-alkoxycarbonyl, (C 1 -C 6 )-alkanoyl, (C 3 -C 8 )-cycloalkylcarbonyl, (C 1 -C 6 )-alkylsulfonyl, aminocarbonyl,

 and (C 1 -C 6 )-alkylaminocarbonyl,

where (C 1 -C 6 )-alkyl and (C 1 -C 6 )-alkanoyl in turn may each be substituted by halogen, hydroxy, (C 1 -C 4 )-alkoxy, (C 1 -C 4 )-alkoxycarbonyl, amino, mono- or di-(C 1 -C 4 )-alkylamino, (C 1 -C 4 )-alkoxycarbonylamino or 5- or 6-membered heterocyclyl having up to two heteroatoms from the series N, O and/or S,

or

R 1 is 5-membered heteroaryl which is linked via a ring nitrogen atom and has up to two further ring nitrogen atoms, and which may be substituted once to three times, identically or differently, by halogen, (C 1 -C 6 )-alkoxycarbonyl or (C 1 -C 6 )-alkyl which is in turn optionally substituted by hydroxy or halogen,

R 2 is (C 6 -C 10 )-aryl which may be substituted once or twice, identically differently, by substituents selected from the group of halogen, nitro, cyano, (C 1 -C 6 )-alkyl, trifluoromethyl, (C 1 -C 6 )-alkanoyl, (C 1 -C 6 )-alkoxy, hydroxy, (C 1 -C 6 )-acyloxy, amino, (C 1 -C 6 )-acylamino, mono- and di-[(C 1 -C 6 )-alkylsulfonyl]amino,

where (C 1 -C 6 )-alkyl and (C 1 -C 6 )-alkoxy in turn may each be substituted by hydroxy, amino, (C 1 -C 4 )-alkoxy or (C 1 -C 4 )-acylamino,

or

R 2 is 5- or 6-membered heteroaryl which has up to two ring nitrogen atoms and which may be substituted by amino, hydroxy, halogen, (C 1 -C 6 )-alkyl or (C 1 -C 6 )-alkoxy,

and

R 3 is hydrogen, halogen, (C 1 -C 6 )-alkyl, trifluoromethyl, nitro, cyano, carboxyl or (C 1 -C 6 )-alkoxycarbonyl,

or a salt, solvate or solvate of a salt thereof.

2. The compound of the formula (I) as claimed in claim 1 ,

in which

R 1 is a group of the formula

in which

A is CR 4 R 5 , O, S, NR 6 or —CH 2 NR 6 —, where

R 4 and R 5 are independently of one another hydrogen, (C 1 -C 4 )-alkyl, which may be substituted by hydroxy, or hydroxy, fluorine, carboxyl or (C 1 -C 4 )-alkoxycarbonyl, or together with the carbon atom to which they are bonded form a carbonyl group,

and

R 6 is hydrogen, (C 2 -C 4 )-alkenyl, (C 3 -C 6 )-cycloalkyl, (C 1 -C 4 )-alkoxycarbonyl, formyl, acetyl, (C 3 -C 6 )-cycloalkylcarbonyl, (C 1 -C 4 )-alkylsulfonyl, aminocarbonyl, (C 1 -C 4 )-alkylaminocarbonyl or is (C 1 -C 4 )-alkyl which in turn may be substituted by hydroxy, methoxy, ethoxy, (C 1 -C 4 )-alkoxycarbonyl, amino, dimethylamino, diethylamino, pyrrolidino, piperidino or morpholino,

or

R 1 is 5-membered heteroaryl which is linked via a ring nitrogen atom and has up to two further ring nitrogen atoms and which may be substituted once or twice, identically or differently, by fluorine, chlorine, (C 1 -C 4 )-alkoxycarbonyl or (C 1 -C 4 )-alkyl which in turn is optionally substituted by hydroxy,

R 2 is phenyl which may be substituted once or twice, identically or differently, by substituents selected from the group of fluorine, chlorine, cyano, (C 1 -C 4 )-alkyl, trifluoromethyl, formyl, acetyl, (C 1 -C 4 )-alkoxy, hydroxy, acetoxy, pivaloyloxy, amino, formylamino, acetylamino and methylsulfonylamino,

where (C 1 -C 4 )-alkyl and (C 1 -C 4 )-alkoxy in turn may each be substituted by hydroxy, amino, methoxy, ethoxy or acetylamino,

or

R 2 is pyrrolyl, pyridyl or pyrimidinyl, each of which may be substituted by amino, fluorine, chlorine, methyl, ethyl, methoxy or ethoxy,

and

R 3 is hydrogen, fluorine, chlorine, bromine, methyl, ethyl, trifluoromethyl, nitro or cyano,

or a salt, solvate or solvate of a salt thereof.

3. The compound of the formula (I) as claimed in claim 1 ,

in which

R 1 is imidazolyl which is attached via a ring nitrogen atom or is piperazinyl which is attached via a ring nitrogen atom and which may be substituted on the second ring nitrogen atom by methyl, ethyl, 2-hydroxyethyl, 2-methoxyethyl, acetyl, tert-butoxycarbonyl or methylsulfonyl,

R 2 is phenyl which may be substituted by fluorine or hydroxy in position 4 relative to the linkage point on the phenyl ring,

and

R 3 is located in position 4 relative to the linkage point of the pyridazinone ring and is hydrogen, fluorine, chlorine, methyl or trifluoromethyl,

or a salt, solvate or solvate of a salt thereof.

4. The compound of the formula (I) as claimed in claim 1 , wherein the compound has one of the following structures:

or a salt, solvate or solvate of a salt thereof.

5. A process for preparing the compounds of the formula (I) as defined in claim 1 , wherein first a compound of the formula (II)

in which

R 3 has the meaning indicated in claim 1 , and

X 1 and X 2 are each halogen,

is converted with a compound of the formula (III)

R 1 —H  (III),

in which R 1 has the meaning indicated in claim 1 ,

into a compound of the formula (IV)

in which R 1 , R 3 and X 2 each have the meaning indicated above,

and the latter is then reacted with a compound of the formula (V)

in which R 2 has the meaning indicated in claim 1 .

6. A pharmaceutical composition comprising at least one compound of the formula (I) as defined in claim 1 , and at least one further excipient.

Assignments (2)
MERGER Recorded Jan 12, 2010
From: BAYER HEALTHCARE AG
To: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
Reel/Frame 023769/0122 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2005
From: SCHOHE-LOOP, RUDOLF; BURCHARDT, ELMAR; FAESTE, CHRISTIANE; HIRTH-DIETRICH, CLAUDIA; KELDENICH, JÖRG; KNORR, ANDREAS; LAMPE, THOMAS; NAAB, PAUL; SCHMIDT, DELF; SCHMIDT, GUNTER
To: BAYER HEALTHCARE AG
Reel/Frame 016200/0333 →